BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rosenbaum E, Kelly C, D'Angelo SP, Dickson MA, Gounder M, Keohan ML, Movva S, Condy M, Adamson T, Mcfadyen CR, Antonescu CR, Hwang S, Singer S, Qin LX, Tap WD, Chi P. A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor. Oncologist 2019;24:1309-e983. [PMID: 31213500 DOI: 10.1634/theoncologist.2019-0418] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Gelderblom H, de Sande MV. Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor. Future Oncol 2020;16:2345-56. [PMID: 32700568 DOI: 10.2217/fon-2020-0542] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Lamb YN. Pexidartinib: First Approval. Drugs. 2019;79:1805-1812. [PMID: 31602563 DOI: 10.1007/s40265-019-01210-0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 19.5] [Reference Citation Analysis]
3 Benner B, Good L, Quiroga D, Schultz TE, Kassem M, Carson WE, Cherian MA, Sardesai S, Wesolowski R. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development. Drug Des Devel Ther 2020;14:1693-704. [PMID: 32440095 DOI: 10.2147/DDDT.S253232] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
4 Zhang SY, Song XY, Li Y, Ye LL, Zhou Q, Yang WB. Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy. Pharmacol Res 2020;161:105111. [PMID: 33065284 DOI: 10.1016/j.phrs.2020.105111] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 Laplagne C, Domagala M, Le Naour A, Quemerais C, Hamel D, Fournié JJ, Couderc B, Bousquet C, Ferrand A, Poupot M. Latest Advances in Targeting the Tumor Microenvironment for Tumor Suppression. Int J Mol Sci 2019;20:E4719. [PMID: 31547627 DOI: 10.3390/ijms20194719] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
6 Ricketts TD, Prieto-Dominguez N, Gowda PS, Ubil E. Mechanisms of Macrophage Plasticity in the Tumor Environment: Manipulating Activation State to Improve Outcomes. Front Immunol 2021;12:642285. [PMID: 34025653 DOI: 10.3389/fimmu.2021.642285] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Vallilas C, Sarantis P, Kyriazoglou A, Koustas E, Theocharis S, Papavassiliou AG, Karamouzis MV. Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules. Int J Mol Sci 2021;22:E493. [PMID: 33419029 DOI: 10.3390/ijms22020493] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Lostes-Bardaji MJ, García-Illescas D, Valverde C, Serrano C. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward. Ther Adv Med Oncol 2021;13:1758835920986498. [PMID: 33473249 DOI: 10.1177/1758835920986498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Arshad J, Ahmed J, Subhawong T, Trent JC. Progress in determining response to treatment in gastrointestinal stromal tumor. Expert Rev Anticancer Ther 2020;20:279-88. [PMID: 32191549 DOI: 10.1080/14737140.2020.1745068] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Martin-Broto J, Moura DS. New drugs in gastrointestinal stromal tumors. Curr Opin Oncol 2020;32:314-20. [PMID: 32541319 DOI: 10.1097/CCO.0000000000000642] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
11 Al-Share B, Alloghbi A, Al Hallak MN, Uddin H, Azmi A, Mohammad RM, Kim SH, Shields AF, Philip PA. Gastrointestinal stromal tumor: a review of current and emerging therapies. Cancer Metastasis Rev 2021;40:625-41. [PMID: 33876372 DOI: 10.1007/s10555-021-09961-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]